Progressive and Reversible Conduction Disease With Checkpoint Inhibitors

Neeti Reddy, Rohit Moudgil, Juan C. Lopez-Mattei, Kaveh Karimzad, Elie N. Mouhayar, Neeta Somaiah, Anthony P. Conley, Shreyaskumar Patel, Dana E. Giza, Cezar Iliescu

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Novel antineoplastic therapies are focused on harnessing our own immune system to fight cancer. To that end, cytotoxic T-lymphocyte–associated antigen 4 and programmed death ligand 1 are 2 coinhibitory signals that play central roles in decreasing T-cell response and represent a class of medications termed “checkpoint inhibitors.” We present an unusual case of progressive conduction abnormalities induced by checkpoint inhibitors. Prompt medical intervention resulted in full recovery. Despite the anticancer efficacy, the newer antineoplastic agents pose a significant and often life-threatening risk of cardiotoxicity.

Original languageEnglish (US)
Pages (from-to)1335.e13-1335.e15
JournalCanadian Journal of Cardiology
Volume33
Issue number10
DOIs
StatePublished - Oct 2017

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Progressive and Reversible Conduction Disease With Checkpoint Inhibitors'. Together they form a unique fingerprint.

Cite this